Q3 2016 13F Holders as of 9/30/2016
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
28M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
12.8M
-
Shares change
-
+283K
-
Total reported value, excl. options
-
$176M
-
Value change
-
+$3.96M
-
Number of buys
-
26
-
Number of sells
-
-4
-
Price
-
$13.87
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) as of Q3 2016
34 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value as of Q3 2016.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value (SYRS) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 12.8M shares
of 28M outstanding shares and own 45.57% of the company stock.
Largest 10 shareholders include Flagship Ventures Management, Inc. (4.81M shares), FMR LLC (3.51M shares), DEERFIELD MANAGEMENT CO (1.81M shares), Redmile Group, LLC (893K shares), Aisling Capital LLC (509K shares), BAKER BROS. ADVISORS LP (204K shares), EVENTIDE ASSET MANAGEMENT, LLC (150K shares), JPMORGAN CHASE & CO (136K shares), BlackRock Fund Advisors (125K shares), and Alyeska Investment Group, L.P. (113K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.